摘要
目的 观察洛铂腹腔热灌注治疗进展期胃癌的有效性及安全性。方法 行标准胃癌根治术的进展期胃癌患者82例分为两组。A组52例,术后行2次洛铂腹腔热灌注化疗,C组30例术后无其他治疗。比较两组术前和术后第6天中性粒细胞与淋巴细胞比值(NLR)和血清肿瘤标记物,观察两组术后不良反应。比较两组总生存率和无瘤生存率。结果 两组术后NLR均低于术前(P<0.05),且A组术后NLR降低更明显(P<0.05)。两组术后癌胚抗原(CEA)、肿瘤异常蛋白、糖类抗原(CA)19-9和CA125均低于术前,且A组术后CEA、CA19-9和CA125下降更明显(P<0.05)。两组术后不良反应发生率相仿(P>0.05)。A组术后总生存率和无瘤生存率均高于C组(P<0.05)。结论 洛铂腹腔热灌注化疗可降低进展期胃癌患者NLR和血清肿瘤标记物水平,延长患者术后无进展生存,不良反应小。
Objective To observe the efficacy and safety of hyperthermic intraperitoneal chemotherapy with lobaplatin in the treatment of advanced gastric cancer.Methods Eighty-two patients with advanced gastric cancer undergoing standard radical gastrectomy were divided into two groups.Group A(52 cases) received two times of hyperthermic intraperitoneal chemotherapy with lobaplatin after operation and group C(30 cases) received no other treatment after operation.The ratio of neutrophil to lymphocyte(NLR) and serum tumor markers were compared between the two groups before and on the 6;day after surgery.Postoperative adverse responses were observed.The overall survival rate and disease-free survival rate were compared between the two groups.Results The postoperative NLR in both groups was lower than that before surgery(P<0.05),which in group A was lower than that in group C(P<0.05).Carcinoembryonic antigen(CEA),abnormal tumor protein, carbohydrate antigen(CA) 19-9 and CA125 in both groups were lower than those before surgery.Serum levels of CEA,CA19-9 and CA125 were decreased more obviously in group A than those in group C(P<0.05).The incidence rates of postoperative adverse responses in the two groups were similar(P>0.05).The overall survival rate and disease-free survival rate in group A were higher than those in group C(P<0.05).Conclusion Hyperthermic intraperitoneal chemotherapy with lobaplatin can reduce the levels of NLR and serum tumor markers in the patients with advanced gastric cancer, prolong their postoperative progression-free survival, and has less adverse responses.
作者
李想
王玉彬
王贵军
尹波
李迪诺
韩向东
齐峰
LI Xiang;WANG Yubin;WANG Guijun(Graduate School,Jinzhou Medical University,Jinzhou 121000,CHINA)
出处
《江苏医药》
CAS
2022年第5期512-515,共4页
Jiangsu Medical Journal
基金
辽宁省自然科学基金(2019JH8/10300031)。
关键词
腹腔热灌注化疗
洛铂
进展期胃癌
Hyperthermic intraperitoneal chemotherapy
Lobaplatin
Advanced gastric cancer
